NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: HeartBeam Inc. Appoints Bryan Humbarger as Chief Commercial Officer and Company Overview
TL;DR
HeartBeam appoints Bryan Humbarger as CCO to drive commercial strategy for its FDA-cleared cardiac tech, potentially accelerating market adoption and competitive edge in portable ECG monitoring.
HeartBeam's new CCO will lead the limited launch of its FDA-cleared system for arrhythmia assessment and heart attack detection, expanding partnerships to validate real-world performance.
HeartBeam's portable 3D ECG technology enables remote cardiac monitoring, improving early detection and care access for heart conditions outside medical facilities.
HeartBeam creates the first cable-free device that synthesizes 3D ECG signals into a 12-lead ECG, revolutionizing portable heart monitoring with FDA-cleared technology.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) has appointed Bryan Humbarger as its new Chief Commercial Officer, effective January 22, 2026, to lead commercial strategy and execution for the company's cardiac care technology.
Bryan Humbarger is the newly appointed Chief Commercial Officer at HeartBeam. In this newly created role, he will lead commercial strategy and execution across key growth initiatives, including the limited launch of the HeartBeam System and expanding outreach to cardiology partners.
HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D and synthesizing them into a 12-lead ECG for portable use outside medical facilities.
HeartBeam has developed a 3D ECG technology platform that includes the HeartBeam System for arrhythmia assessment, heart attack detection, and a 12-lead ECG extended wear patch monitor. The technology received FDA clearance for arrhythmia assessment in December 2024 and for the 12-Lead ECG synthesis software in December 2025.
Humbarger will lead the limited launch of the recently cleared HeartBeam System for arrhythmia assessment and heart attack detection, manage the 12-lead ECG extended wear patch monitor initiative, and expand outreach to cardiology partners to validate real-world performance and establish reference sites for broader adoption.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance in December 2025.
Detailed information about the intended use of HeartBeam's technology can be found in the Company's Cleared Indications for Use at https://www.heartbeam.com/indications.
The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
BioMedWire is a specialized communications platform focused on developments in Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is part of the Dynamic Brand Portfolio @ IBN that distributes content through wire solutions, syndication to 5,000+ outlets, press release enhancement, and social media distribution.
HeartBeam's technology enables physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of cardiac health management through portable, actionable heart intelligence.
Curated from InvestorBrandNetwork (IBN)
